It is our great pleasure to let you know that the protocol for the SENTIX trial (SENTinel lymph node in cervIX cancer) has been finished and the trial is now ready for new centers to join it and for new patients to be enrolled in.

SENTIX is a prospective observational international multicenter trial on sentinel lymph node biopsy in patients with early stage of cervical cancer. Our target is to enroll 300 patients and this could be achieved until the end of 2017.The trial chair is David Cibula, and the main investigator is Roman Kocian (General University Hospital in Prague, CZ). 

Since the SENTIX is the original CEEGOG trial it is our hope that the majority of CEEGOG centers will participate in it.

We are looking forward to our prospective mutual cooperation.  For futher information or if you have any queries, please do not hesitate to contact the CEEGOG office.